重大事件
即時報告
8-K
2026-08-10
OSR Health股東會通過增發授權股本及重選七名董事 投票率60.05%
AI 繁中摘要
OSR Health, Inc.（納斯達克：OSRH / OSRHW）於2026年8月7日舉行股東週年大會，並已向SEC提交8-K文件披露投票結果。截至2026年7月8日記錄日期，公司已發行在外普通股為35,118,692股，每股可享有一票投票權；是次會議共有21,088,120股股份親身或委託代表出席，約佔合資格投票股份的60.05%，達到法定人數。
會議共處理四項議案。第一，重選七名董事，全部獲得通過，將任期至2027年股東週年大會為止。當選董事包括Kuk Hyoun Hwang、Jun Chul Whang、Alcide Barberis、Seng Chin Mah、Hyuk Joo Jee、Joong Myung Cho及Reto Fierz；各人贊成票數介乎約1,517萬至1,518.5萬股，反對或 withheld 票數極少。
第二，批准續聘獨立核數師，投票結果為20,296,535票贊成、201,444票反對、590,141票棄權，順利通過。第三，股東就高層管理人員薪酬進行諮詢表決，結果為15,059,135票贊成、83,113票反對、161,533票棄權，獲通過。第四，增加授權股本議案亦獲通過，贊成票19,922,498票，反對581,009票，棄權584,613票。
是次8-K純粹披露股東會投票結果，並無提供管理層對未來業績或營運前景的最新展望。對投資者而言，最值得留意的是增加授權股本議案獲批，意味公司未來可發行更多股份，可能用於融資、收購或激勵計劃，或會帶來攤薄效應。至於董事會成員全部順利連任，反映股東對現有管治團隊支持度維持穩定；高層薪酬方案獲通過，亦減低短期內出現股東爭議的風險。整體而言，投票結果符合預期，對公司股價的直接影響應屬中性偏正面，但長遠需觀察公司是否會動用新增授權股本進行大額集資。
展開英文正文
false 0001840425 0001840425 2026-08-07 2026-08-07 0001840425 OSRH:CommonStockParValue0.0001PerShareMember 2026-08-07 2026-08-07 0001840425 OSRH:RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2026 OSR HEALTH, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-41390 84-5052822 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.) 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code (425) 635-7700 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share OSRH The Nasdaq Stock Market LLC Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share OSRHW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders On August 7, 2026, the Company held an annual meeting of its stockholders (the “Annual Meeting”). As of the close of business on July 8, 2026, the record date for the Annual Meeting, there were 35,118,692 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), issued and outstanding, each of which was entitled to one vote with respect to each of the proposals presented at the Annual Meeting. A total of 21,088,120 shares of Common Stock, representing approximately 60.05% of the outstanding shares of Common Stock entitled to vote at the Annual Meeting, were present in person or by proxy, constituting a quorum. The proposals listed below are described in more detail in the Definitive Proxy Statement on Form DEF 14A filed by the Company with the SEC on July 16, 2026 (the “Proxy Statement”). Director Proposal At the Annual Meeting, stockholders re-elected seven (7) directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified. The final voting results were as follows: FOR WITHHELD RESULT Kuk Hyoun Hwang 15,174,735 129,046 Elected Jun Chul Whang 15,175,735 128,046 Elected Alcide Barberis 15,185,385 118,396 Elected Seng Chin Mah 15,170,280 133,501 Elected Hyuk Joo Jee 15,174,735 129,046 Elected Joong Myung Cho 15,170,315 133,466 Elected Reto Fierz 15,179,965 123,816 Elected Ratification of Independent Auditor Proposal The stockholders approved the Ratification of Independent Auditor Proposal by the votes set forth in the table below: FOR AGAINST ABSTAIN 20,296,535 201,444 590,141 Executive Compensation Proposal The stockholders approved the Executive Compensation Proposal by the votes set forth in the table below: FOR AGAINST ABSTAIN 15,059,135 83,113 161,533 Authorized Shares Increase Proposal The stockholders approved the Authorized Shares Increase Proposal by the votes set forth in the table below: FOR AGAINST ABSTAIN 19,922,498 581,009 584,613 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 10, 2026 OSR HEALTH, INC. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer 2